Recall record at a glance
| Official record | F-1750-2014 |
|---|---|
| Category | Food Recalls |
| Classification | Class II |
| FDA record status | Terminated |
| Recalling firm | keen-wah LLC |
| Report date | Apr 16, 2014 |
| Recall initiation date | Mar 28, 2014 |
| Quantity | approximately 4899 cs - 4 oz 12 units/case; approximately 475 cs - 1 oz 24 units/cs |
| Location | Chicago, IL, United States |
Official product description
i heart keenwah Almond All Natural Quinoa Clusters. UPC 736211802347 for the 4 oz UPC 713757598200 for the 1 oz
Why the product was recalled
An anti-stick spray containing soy lecithin was used during the manufacture of several varieties of i heart keenwah, quinoa clusters and soy was not declared on the product labeling.
Distribution information
Nationwide and Canada
How to read the classification
FDA Class II indicates a situation in which use of or exposure to the product may cause temporary or medically reversible adverse health consequences, or where the probability of serious consequences is remote. The classification shown here comes from the FDA record.
Additional record details
Recall type: Voluntary: Firm initiated. Initial notification: Telephone.
What to do next
If you believe you have the recalled product, use the recall number and firm information above to confirm the official notice and follow the instructions issued by the FDA, recalling firm, retailer or product manufacturer. For drugs and medical devices, decisions about treatment or medical care should be discussed with a qualified health professional.
About this record
Recall Lookup USA preserves the most complete source information successfully retrieved. We do not create missing facts or infer affected lots or VINs. The official record may still change, so use the identifier above when verifying current instructions.
FDA source limitation: openFDA enforcement reports are a reference dataset, not a live public-alert or recall-lifecycle service. FDA notes that enforcement-report status may not be updated after classification. Confirm current actions with the FDA, recalling firm or appropriate healthcare professional when relevant.